BEGIN ARTICLE PREVIEW:
September 15, 2020
BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company specializing in vertebral and knee-surgery implants, announces its results for the first half of the year to June 30, 2020, as approved by the Board of Directors on September 15, 2020.
Implanet CEO Ludovic Lastennet said: “These first-half results illustrate the slowdown in activity due to the COVID-19 pandemic, embodied by the halting and postponement of scheduled surgical operations since March. Measures implemented in early spring have enabled us to navigate this period as best as possible. We reacted swiftly, and the decrease in activity was partly offset by adapting our cost structure and managing our operations in France and abroad. The latest trends confirm the gradual upturn in activity, we anticipate recovering a portion of the lost revenue we were unable to generate during this period during the second half of the year. Nevertheless, we are keeping a close eye on the continually changing public health situation and will activate every lever at our disposal in order to pursue our development by capitalizing on Implanet’s assets and product ranges”.
In € thousands – IFRS* H1 2020 H1 2019 Change (%)Revenue 2,595 3,818 -32% …
END ARTICLE PREVIEW